Praxis Precision Medicines, Inc. sold the stake/assets to Tenacia Biotechnology (Shanghai) Company, Ltd. as part of a licensing/collaboration on 2024-01-02.
Deal value was 150000000 (source: Extracted) Sector: Biopharmaceuticals; Location: Shanghai.
On the seller side, Sidley Austin advised, led by Asher Rubin, Adriana V. Tibbitts, Collin J Marshall.
Generated by AI, original source from - Data is in progress
Found it useful? Spread the word.
Sidley represents Praxis Precision Medicines in licensing and collaboration agreement with Tenacia Biotechnology for Ulixacaltamide in Greater China | The Sponsor - The Sponsor
